Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Jun. 30, 2015		Jun. 30, 2014		Jun. 30, 2013
Income Statement [Abstract]
Revenue	$ 102,531		$ 91,084		$ 101,093
Cost of products sold	96,819		85,923		96,172
Gross margin	5,712		5,161		4,921
Operating expenses:
Distribution, selling, general and administrative expenses	3,240		3,028		2,875
Restructuring and employee severance	44	[1]	31	[2]	71	[3]
Amortization and other acquisition-related costs	281		223		158
Impairments and (gain)/loss on disposal of assets, net	(19)		15		859
Litigation (recoveries)/charges, net	5		(21)		(38)
Operating earnings	2,161		1,885		996
Other income, net	(7)		(46)		(15)
Interest expense, net	141		133		123
Loss on extinguishment of debt	60		0		0
Earnings before income taxes and discontinued operations	1,967		1,798		888
Provision for income taxes	755		635		553
Earnings from continuing operations	1,212		1,163		335
Earnings/(loss) from discontinued operations, net of tax	3		3		(1)
Net earnings	$ 1,215		$ 1,166		$ 334
Basic earnings per common share:
Continuing operations (in dollars per share)	$ 3.65		$ 3.41		$ 0.98
Discontinued operations (in dollars per share)	0.01		0.01		0.00
Net basic earnings per common share (in dollars per share)	3.66		3.42		0.98
Diluted earnings per common share:
Continuing operations (in dollars per share)	3.61		3.37		0.97
Discontinued operations (in dollars per share)	0.01		0.01		0.00
Net diluted earnings per common share (in dollars per share)	$ 3.62		$ 3.38		$ 0.97
Weighted-average number of common shares outstanding:
Basic (in shares)	332		341		341
Diluted (in shares)	335		345		344

[1] The majority of the restructuring and employee severance incurred during fiscal 2015 were related to restructuring activities within our Medical segment.

[2] Includes $10 million of primarily facility exit and other costs related to the restructuring within our Medical segment described further below.

[3] Includes $30 million of employee-related costs and $10 million of facility exit and other costs related to the restructuring within our Medical segment described further below.